8-K: Onconetix Secures Nasdaq Listing Extension, Implements 1-for-85 Reverse Stock Split

Onconetix, Inc. announced it received a decision from the Nasdaq Hearings Panel granting its request for continued listing, subject to demonstrating compliance with listing rules by June 30, 2025, following a recent reverse stock split.

Summary

• Onconetix, Inc. received a decision from the Nasdaq Hearings Panel on June 11, 2025, granting its request for continued listing on The Nasdaq Stock Market.
• The continued listing is contingent upon the company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) (Periodic Filing Listing Rule) by June 13, 2025, and Nasdaq Listing Rule 5250(c)(1) (Bid Price Listing Rule) on or before June 30, 2025.
• The Nasdaq hearing on this matter was held on May 27, 2025.
• Onconetix successfully demonstrated compliance with the Periodic Filing Listing Rule on June 12, 2025, by filing its Form 10-Q for the period ended March 31, 2025.
• To address the Bid Price Listing Rule, the company completed a 1-for-85 reverse stock split of its outstanding common stock at 12:01 a.m. Eastern Time on June 13, 2025.
• Onconetix anticipates demonstrating compliance with the Bid Price Listing Rule by the close of business on June 27, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive because the company successfully secured continued listing on Nasdaq, avoiding immediate delisting. However, the underlying issues that led to the hearing (low bid price, past filing non-compliance) and the necessity of a significant 1-for-85 reverse stock split temper the positivity, indicating ongoing challenges and risks.

Positives

• The Nasdaq Hearings Panel granted Onconetix's request for continued listing on The Nasdaq Stock Market, averting immediate delisting.
• The company successfully demonstrated compliance with the Nasdaq Periodic Filing Listing Rule on June 12, 2025, by timely filing its Form 10-Q.

Negatives

• The company required a Nasdaq Hearings Panel decision to maintain its listing, indicating prior non-compliance with listing rules.
• A significant 1-for-85 reverse stock split was necessary to meet the Nasdaq Bid Price Listing Rule, reflecting a substantially low share price prior to the split.

Risks

• Failure to regain and maintain compliance with Nasdaq's applicable listing criteria, potentially leading to delisting.
• The effect of a potential delisting from Nasdaq on the market for the company's securities.
• Uncertainty regarding the entry into or completion of a definitive agreement for the proposed transaction with Therapeutics, Inc. (Ocuvex) and any related financing.
• Risk that proposed transactions may be completed with different terms, in an untimely manner, or not at all.
• Inability to realize the anticipated benefits of a proposed transaction with Ocuvex.
• Challenges in integrating the assets and commercial operations contemplated to be acquired from Ocuvex into the company's business.
• Risks related to Onconetix's ability to commercialize or monetize Proclarix and integrate its assets and commercial operations.
• Present need for capital to commercially launch Proclarix and ensure adequate working capital.
• Risks related to attracting, hiring, and retaining skilled personnel necessary to commercialize and operate the company's commercial products.
• Failure to obtain and maintain necessary regulatory approvals to market and commercialize Onconetix's products.
• Risks related to the company's ability to obtain and maintain intellectual property protection for its current products.
• Reliance on third parties, including manufacturers and logistics companies.
• Significant inherent risks in the development, regulatory approval, and commercialization of biotechnology products.

Future Outlook

Onconetix expects to demonstrate compliance with the Nasdaq Bid Price Listing Rule by the close of business on June 27, 2025. The company also mentions potential future transactions, including a proposed transaction with Ocuvex (Therapeutics, Inc.) and related financing, and its ongoing efforts to commercialize Proclarix.

Management Comments

• "The Company expects to demonstrate compliance with the Bid Price Listing Rule at the close of business on June 27, 2025."

Industry Context

Onconetix operates as a commercial-stage biotechnology company specializing in mens health and oncology, with its primary product, Proclarix, an in vitro diagnostic test for prostate cancer approved in the EU. The ability to maintain a Nasdaq listing is critical for biotech companies to access capital, maintain investor confidence, and ensure liquidity, especially for those in commercialization stages that typically require significant funding for product launch and ongoing operations.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Onconetix's performance against global benchmarks.
• The necessity of a reverse stock split and the prior Nasdaq compliance issues suggest that Onconetix has faced significant challenges in maintaining its share price and meeting listing requirements, which can be a red flag when compared to more stable, well-capitalized biotech peers.

Stakeholder Impact

• Shareholders: Positive impact from continued Nasdaq listing, which helps maintain liquidity and investor confidence. Negative impact from the 1-for-85 reverse stock split, which significantly reduces the number of shares held, although the total value should theoretically remain the same.
• Employees: Continued operations and stability due to maintained listing.
• Customers: No direct immediate impact mentioned, but continued listing can enhance company credibility and long-term viability.
• Creditors/Suppliers: Maintained listing can improve the company's financial standing and ability to raise capital, potentially benefiting relationships.

Next Steps

• Demonstrate compliance with the Nasdaq Bid Price Listing Rule 5250(c)(1) on or before June 30, 2025.
• Continue efforts to commercialize Proclarix.
• Potentially pursue and complete a proposed transaction with Therapeutics, Inc. (Ocuvex) and related financing.

Key Dates

Recommendation

Keywords

Onconetix, Nasdaq, Listing Compliance, Reverse Stock Split, Biotechnology, Mens Health, Oncology, Proclarix, SEC Filing, 8-K, Stock Market, Delisting Risk, Corporate Governance